Liquid biopsy-based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC)

被引：0
|
作者：
Bortot, L. [1 ]
Basile, D. [2 ]
Palmero, L. [1 ]
Dri, A. [1 ]
Cucciniello, L. [1 ]
Buriolla, S. [1 ]
Pasto, B. [1 ]
Mazzeo, R. [1 ]
Bonotto, M. [3 ]
Bolzonello, S. [4 ]
Franzoni, A. [5 ]
Allegri, L. [5 ]
Belletti, B. [6 ]
Damante, G. [1 ]
Gerratana, L. [7 ]
Minisini, A. M. M. [3 ]
Puglisi, F. [8 ,9 ]
机构：
[1] Univ Udine, Dept Med DAME, Udine, Italy
[2] San Giovanni Dio Hosp, Med Oncol Unit, Crotone, Italy
[3] Azienda Sanitaria Univ Friuli Cent ASUFC, Santa Maria Misericordia Acad Hosp, Dept Oncol, Udine, Italy
[4] Ctr Riferimento Oncologico CRO, Dept Med Oncol, IRCCS, Aviano, Italy
[5] Azienda Sanitaria Univ Friuli Centrale ASUFC, Inst Human Genet, Udine, Italy
[6] Ctr Riferimento Oncol Aviano CRO, Mol Oncol Unit, IRCCS, Aviano, Italy
[7] Ctr Riferimento Oncol CRO, Dept Med Oncol, IRCCS, Aviano, Italy
[8] Univ Udine, Dept Med DAME, Udine, Italy
[9] Univ Udine, Dept Med DAME, Pordenone, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.300
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
261P
引用
收藏
页码：S656 / S657
页数：2
相关论文
共 50 条
  • [21] Unravelling tumor heterogeneity in patients with HER2-low hormone receptor-positive breast cancer using spatial transcriptomics
    Fimereli, Danai
    Serra, Matteo
    Rediti, Mattia
    Lifrange, Frederic
    Occelli, Nicola
    Collet, Laetitia
    Vincent, Delphine
    Rouas, Ghizlane
    Craciun, Ligia
    Larsimont, Denis
    Venet, David
    Vikkula, Miikka
    Duhoux, Francois P.
    Rothe, Francoise
    Sotiriou, Christos
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Unravelling tumor heterogeneity in patients with HER2-low hormone receptor-positive breast cancer using spatial transcriptomics
    Fimereli, D.
    Serra, M.
    Rediti, M.
    Lifrange, F.
    Occelli, N.
    Collet, L.
    Vincent, D.
    Rouas, G.
    Craciun, L.
    Larsimont, D.
    Venet, D.
    Vikkula, M.
    Duhoux, F. P.
    Rothe, F.
    Sotiriou, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 100 - 100
  • [23] Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)
    Paplomata, E.
    Gogineni, K.
    Meisel, J.
    Santa-Maria, C.
    Yuan, L.
    Kramer, J.
    Li, X. Bill
    Zelnak, A.
    Pakkala, S.
    Kaklamani, V.
    O'Regan, R.
    CANCER RESEARCH, 2017, 77
  • [24] Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)
    Cucciniello, L.
    Noto, C.
    Bolzonello, S.
    Molteni, E.
    Da Ros, L.
    Pasto, B.
    Franzoni, A.
    Spazzapan, S.
    Russo, S.
    Foffano, L.
    Buriolla, S.
    Targato, G.
    Allegri, L.
    Dri, A.
    Della Rossa, S.
    Bonotto, M.
    Damante, G.
    Belletti, B.
    Gerratana, L.
    Puglisi, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S357 - S357
  • [25] Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2-metastatic breast cancer
    Dieras, V.
    Hamilton, E.
    Johnston, E. L.
    Forrester, T.
    Martin, M.
    CANCER RESEARCH, 2017, 77
  • [26] Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)
    Chumsri, S.
    Sammons, S.
    Alder, L.
    Sokol, E.
    Danziger, N. A.
    Raskina, K.
    Schrock, A. B.
    Venstrom, J.
    Snow, T.
    Castellanos, E.
    Ochuonyo, E.
    Snider, J.
    Mcgregor, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S462 - S463
  • [27] Effect of cyclin-dependent kinase 4 and 6 inhibitors (CDKIs) on body composition (BC) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
    Phuong, Lisa
    Patel, Janki
    Baka, Nadia
    Goldman, Jessica
    Lyudmer, Michael
    Shamir, Stephanie
    Deng, Junwen
    Soto, Alvaro Alvarez
    Anampa Mesias, Jesus Del Santo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] EGF114299: Safety and Efficacy of an Aromatase Inhibitor (AI) in Combination with Lapatinib (L), Trastuzumab (T) or Both for the Treatment of Hormone Receptor-Positive (HR+), HER2+Metastatic Breast Cancer (MBC).
    Johnston, S.
    Leigh, M.
    Florance, A.
    Wroblewski, S.
    Gradishar, W.
    CANCER RESEARCH, 2011, 71
  • [29] Development and validation of RSClin N plus tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer
    Pusztai, Lajos
    Hoag, Jess R.
    Albain, Kathy S.
    Barlow, William E.
    Stemmer, Salomon M.
    Meisner, Allison
    Hortobagyi, Gabriel N.
    Shak, Steven
    Hayes, Daniel F.
    Rae, James M.
    Baehner, Frederick
    Sharma, Priyanka
    Kalinsky, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] LapatinibIn Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer
    Monique P. Curran
    Drugs, 2010, 70 : 1411 - 1422
12345